In various cancer models, HDAC antagonists have a synergistic relationship with PI3K inhibitors that is associated with a strong inhibition of the PI3K/AKT signaling pathway compared to single-agent PI3K inhibitor [81, 82]. The gene discussed is PIK3CA; the disease is cancer.